MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk NVO has outperformed the market over the past 5 years by 3.16% on an annualized basis producing an average ...

Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this ...

Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company that specializes in diabetes care and other chronic ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) and reminds investors of the ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...

The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations.

StockNews.com downgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a strong-buy rating to a buy rating in a ...